Genmab A/S Stock News

Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) pr...

Company Announcement COPENHAGEN, Denmark; October 7, 2026 –  Genmab A/S  (Nasdaq: GMAB)  Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was approved.

The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities NORTH CHICAGO, Ill. and COPENHAGEN, ...

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and Abb...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S...

Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC) Antitumor activity was observed regardless of folate receptor alpha (FRα) expression levels, including low FRα expression ...

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited (“Darwin”) has informed us that, as of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwi...